Share This Article

Facebook LinkedIn
Twitter Reddit
Print Email
Pinterest Gmail
Yahoo
Money Morning
×
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • Angel Investing
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
  • Retire
    • Income Investing Guide
    • Retirement Articles
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
Login My Member Benefits Archives Research Your Team About Us FAQ
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • Angel Investing
    ×
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
    ×
  • Retire
    • Income Investing Guide
    • Retirement Articles
    ×
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
    ×
  • Subscribe
Enter stock ticker or keyword
×
5 Ways to Beat the Fed (and Crush Inflation)

Email this Article

Send with mail | ahoo instead.
Required Needs to be a valid email
Required Needs to be a valid email
How to Identify the Real Winners of the COVID-19 Vaccine Race
https://moneymorning.com/?p=1147005
Required Please enter the correct value.
Twitter
Stocks: MRK, MRNA, SRNE

How to Identify the Real Winners of the COVID-19 Vaccine Race

By Michael A. Robinson, Defense + Tech Specialist, Money Morning • @Robinson_STI • May 29, 2020

Start the conversation

Comment on This Story Click here to cancel reply.

Or to contact Money Morning Customer Service, click here.

Your email address will not be published. Required fields are marked *

Some HTML is OK

Michael A. RobinsonMichael A. Robinson

Living in California where we have had the fourth-highest amount of cases of any state, I've seen firsthand the dramatic impact of the coronavirus on our daily lives.

Storefronts have closed, and major San Francisco employers, like Facebook, have given employees the option to work from home indefinitely.

Of course, some cities have started to open back up, but it has not been a great start. There's still plenty of uncertainty out there. Cases have risen in Houston, and Virginia just reported its highest per-day increase of COVID-19 cases.

This is why the need for a vaccine is so important and why the biopharma industry has received such close attention by the public and investors over the last few months.

The Massive Profit Potential for Coronavirus Vaccines

Since the start of the pandemic, we have seen almost 100 companies and universities across the world announce the development of vaccines to protect against this disease.

The site Clinicaltrials.gov, which is a database of privately and publicly funded clinical studies, shows over 1,500 studies and trials are underway for COVID-19. From giant pharmaceutical companies all the way down to small biotechs, everyone is headed toward the same goal.

With all the money coming into this space, it has helped many of these biotech companies get up and running faster than ever before. In fact, we have recently seen some of these small biotech companies skyrocket over 100% with announcements around vaccine trials and early results.

While this may sound like a big jump, with billions of people potentially needing a vaccine, we are still in the early innings of curing this disease. Most companies are researching a vaccine or have just started phase 1 trials, which is the beginning of a process that could end up taking over a year. Experts, including the U.S. Federal Reserve Chair Jerome Powell, also believe that complete economic recovery is only possible once a vaccine against the novel coronavirus is discovered.

Even though several companies may make it past their phase 1 trials, historically, just 6% of vaccine candidates end up making it to market.

This is why I've done hundreds of hours of research into every one of these potential vaccines.

During my search for the best-positioned drugs, I've also identified companies that you should stay away from because it's just as important to know the companies to stay away from as it is the companies with the best opportunity to develop a cure.

Putting Coronavirus Cures Under the Microscope

On May 18, Moderna Inc. (NASDAQ: MRNA) announced that it had positive interim phase 1 data for its mRNA vaccine (mRNA-1273). Shortly after this announcement containing limited data, its stock price rose almost 30%. That evening, after the stock had risen considerably, Moderna announced it planned to raise $1.25 billion in a secondary offering.

Now this may not raise any red flags on the surface, but having dug through the data, I decided to stay away from this one.

The first issue for me was that there were no significant details on the study, and nothing was published in a journal. On top of that, the study only involved 45 participants, which is a very small scale.

Secondly, I always look at the history of a company. While Moderna has other vaccines in its pipeline, it has never brought a drug to market based on mRNA technology.

As a former journalist, I decided to dig in even further into the stock offering and saw that executives of the company have sold nearly $30 million of stock after the offering.

While these sales were executed under a 10b5-1 trading plan and were not breaking any rules, I always like to invest with executives who keep their money in the company as a sign of faith in what they are doing.

We saw a big jump in Sorrento Therapeutics Inc. (NASDAQ: SRNE), another company looking to develop a vaccine, and not a single executive sold stock after it rose over 100%. For these reasons, I have decided that there are other companies conducting trials that I would rather invest in.

Take Merck & Co. Inc. (NYSE: MRK), the $200 billion multinational pharmaceutical company.

It has recently made three major announcements. It announced two vaccine candidates with partners Ridgeback Bio and IAVI, and plans to acquire Themis Bioscience, a company focused on vaccines and immune modulation therapies for infectious diseases.

While Merck has been relatively quiet up until now, CEO Ken Frazier stated that he was "waiting for opportunities with a proven track record" and in a single dose. This is a much different strategy than many of the biotech companies looking to develop a vaccine.

Given Merck's background in developing vaccines, including its recent Ebola vaccine, it could be very well positioned in finding a working vaccine for COVID-19.

As I mentioned earlier, only a few vaccines in trial may make it to market, so I make sure to spend hundreds of hours of research into dozens of companies in order to identify the drugs that have the best chance of helping millions of people.

I have even spoken with CEOs on the state of their vaccines to find out who may be the best candidate to get a vaccine to market.

And this is exactly why I've put together a special presentation...

You see, over 70 firms are racing to produce the most critical vaccine of all time, but only one of them can give you a shot at making 3,000%...

Click here to learn more...

Follow Money Morning on Facebook and Twitter.

Join the conversation. Click here to jump to comments…

Michael A. RobinsonMichael A. Robinson

About the Author

Browse Michael's articles | View Michael's research services

Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...

  • He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
  • He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
  • As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.

This all means the entire world is constantly seeking Michael's insight.

In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.

Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.

And even with decades of experience, Michael believes there has never been a moment in time quite like this.

Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.

To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.

His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.

… Read full bio

Login
guest
guest
0 Comments
Inline Feedbacks
View all comments
LIVE
Visit Money Morning Live


Latest News

January 19, 2023 • By Money Morning Stock Research Team

These Stocks Could Go To $0

January 9, 2023 • By Money Morning Stock Research Team

The Government Is Pouring $391 Billion Into These Stocks - Buy Now

December 27, 2022 • By Money Morning Staff Reports

6 IPOs in 2023 You Can’t Afford to Miss
Trending Stories
ABOUT MONEY MORNING

Money Morning gives you access to a team of market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.

QUICK LINKS
About Us COVID-19 Announcements How Money Morning Works FAQs Contact Us Search Article Archive Forgot Username/Password Archives Profit Academy Research Your Team Videos Text Messaging Terms of Use
FREE NEWSLETTERS
Total Wealth Research Power Profit Trades Profit Takeover This Is VWAP Penny Hawk Trading Today Midday Momentum Pump Up the Close
PREMIUM SERVICES
Money Map Press Home Money Map Report Fast Fortune Club Weekly Cash Clock Night Trader Microcurrency Trader Hyperdrive Portfolio Rocket Wealth Initiative Extreme Profit Hunters Profit Revolution Warlock's World Penny Nation Quantum Data Profits Live Trading Alliance Trade The Close Inside Money Trader Expiration Trader Vega Burst Trader Flashpoint Trader Darknet Hyper Momentum Trader

© 2023 Money Morning All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning.

Address: 1125 N Charles St. | Baltimore, MD, 21201 | USA | Phone: 888.384.8339 | Disclaimer | Sitemap | Privacy Policy | Whitelist Us | Do Not Sell My Info

wpDiscuz